It is worth noting that the accumulated balance of the medical insurance fund is used in the medical insurance fund, which will not affect the income and expenditure of the current medical insurance fund, nor will it affect the treatment of the insured.
Earlier, some people in China reported that emergency vaccination was charged. Ceng Yixin said that he had issued a document on behalf of the comprehensive group of joint defense and control mechanism in the State Council, demanding immediate rectification.
Domestic vaccines can be divided into class I vaccines and class II vaccines according to different payers. One kind of vaccine, the national immunization program vaccine, is provided by the government to citizens free of charge, including hepatitis B vaccine and BCG vaccine for infants. Class II vaccines refer to other vaccines that residents voluntarily vaccinate, such as influenza vaccine.
The national immunization program holds a meeting at least once a year to discuss whether to update the first vaccine and adjust and optimize the use procedures of the original vaccine. However, the final decision needs to consider the adjustment plan according to the comprehensive aspects of public health demand, finance, public health implementation capacity and vaccine accessibility.
In the past, the first-level seedling expenditure did not involve the medical insurance fund, but was directly paid by the financial expenditure. NPC representatives discussed with the government whether the COVID-19 vaccine should be paid by the medical insurance fund. Some deputies suggested that pneumonia vaccine, the new crown, be included in the full reimbursement of medical insurance, but in June 5438+ 10, 2020, the National Medical Insurance Bureau replied, "The current basic medical insurance system still focuses on providing basic disease treatment for the masses, focusing on meeting the basic medical needs of the masses, and has not been able to extend the scope of payment to non-therapeutic items such as vaccines."
However, another problem is that if COVID-19's vaccines are completely funded by finance, it may cause greater financial pressure.
According to the announcement of the negotiation on the emergency procurement of vaccines for emergency use in novel coronavirus, Anhui Province, the purchase price of inactivated vaccines in novel coronavirus of Beijing Kexing Zhongwei, Beijing Institute of Biological Products and Wuhan Institute of Biological Products in Anhui Province is 200 yuan/bottle or branch.
According to the domestic population of 654.38+0.39 billion, if the future vaccine purchase price reduction is not considered, the single vaccine purchase expenditure in COVID-19 will exceed 550 billion yuan. This has not taken into account the transportation cost of the vaccine and the labor cost incurred in the injection process.
However, according to National Health Commission's Statistical Bulletin on Health Development in China in 20 19, the total health expenditure in 20 19 exceeded 6.5 trillion, of which the government health expenditure was about 1.74 trillion. If all the expenses of the new vaccine go through government health expenditure, it may squeeze other health expenditure.
The accumulated balance of medical insurance fund mentioned by Li Tao at the press conference of joint prevention and control mechanism is the cumulative sum of the balance of medical insurance fund over the years.
According to the statistical express of medical security development in 20 19 published by the national medical insurance bureau, the accumulated balance of the basic medical insurance fund in 2065438 was+0.2.11100 million yuan. Previously, the excessive balance of medical insurance fund was considered by some scholars to deviate from the principle of "balance of payments and a slight balance", which was easy to produce "misappropriation impulse".
However, in the past two years, the growth of basic medical insurance fund financing (19.3% and 9. 1%) has been lower than that of expenditure (23.6% and1/0/.9%), and the pressure of medical insurance fund expenditure has increased. Whether it will affect the balance fund in the future is still unknown.
In addition, some scholars have previously worried whether the direct inclusion of COVID-19 vaccine in the national immunization program will affect the fund withdrawal of vaccine enterprises, which will eventually lead to insufficient research and development motivation and investment in the future.
Li Tao said at the news conference that with the continuous expansion of vaccine production scale and vaccination scale in COVID-19, COVID-19, there are more and more products on the market, and the prices will change accordingly. "Relevant government departments will also take measures to formulate a corresponding price formation mechanism to introduce the price of the new crown vaccine into an economic and reasonable range."